Some animal studies suggest that beta-adrenoceptor-mediated vasorelaxation is in part mediated through nitric oxide (NO) release. Furthermore, in humans, we have recently shown that forearm blood flow is increased by infusion of beta2-adrenergic agonists into the brachial artery, and the nitric oxide synthase (NOS) inhibitor N(G)-monomethyl-L-arginine (L-NMMA) inhibits this response. 2. The purpose of the present study was to determine whether stimulation of human umbilical vein endothelial beta-adrenoceptors causes vasorelaxation and nitric oxide generation, and whether this might be mediated by cyclic adenosine-3',5'-monophosphate (cyclic AMP). 3. Vasorelaxant responses were determined in umbilical vein rings to the nonselective beta-adrenergic agonist isoprenaline and to the cyclic AMP analogue dibutyryl cyclic AMP, following precontraction with prostaglandin F2alpha. 4. NOS activity was measured in cultured human umbilical vein endothelial cells (HUVEC) by the conversion of [3H]-L-arginine to [3H]-L-citrulline, and adenylyl cyclase activity by the conversion of [alpha-32P]-ATP to [32P]-cyclic AMP. 5. Isoprenaline relaxed umbilical vein rings, and this vasorelaxation was abolished by beta2- (but not beta1-) adrenergic blockage, and by endothelium removal or 1 mM L-NMMA. In addition, vasorelaxant responses to dibutyryl cyclic AMP were inhibited by 1 mM L-NMMA, with a reduction in Emax from 90.0+/-9.3% to 50.5+/-9.9% (P<0.05). 6. Isoprenaline 1 microM increased NOS activity in HUVEC (34.0+/-5.9% above basal, P<0.001). Furthermore, isoprenaline increased adenylyl cyclase activity in a concentration-dependent manner; this response was inhibited by beta2 (but not beta1-) adrenergic blockade. Forskolin 1 microM and dibutyryl cyclic AMP 1 mM each increased NOS activity in HUVEC, to a degree similar to isoprenaline 1 microM. The increase in L-arginine to L-citrulline conversion observed with each agent was abolished by coincubation with NOS inhibitors. 7. These results indicate that endothelial beta2-adrenergic stimulation and cyclic AMP elevation activate the L-arginine/NO system, and give rise to vasorelaxation, in human umbilical vein.
摘要
一些动物研究表明,β-肾上腺素能受体介导的血管舒张部分是通过一氧化氮(NO)释放来介导的。此外,在人类中,我们最近发现,向肱动脉内输注β2-肾上腺素能激动剂可增加前臂血流量,而一氧化氮合酶(NOS)抑制剂N(G)-单甲基-L-精氨酸(L-NMMA)可抑制这种反应。2. 本研究的目的是确定刺激人脐静脉内皮β-肾上腺素能受体是否会引起血管舒张和一氧化氮生成,以及这是否可能由环腺苷-3',5'-单磷酸(环磷酸腺苷)介导。3. 在前列腺素F2α预收缩后,测定脐静脉环对非选择性β-肾上腺素能激动剂异丙肾上腺素和环磷酸腺苷类似物二丁酰环磷酸腺苷的血管舒张反应。4. 通过将[3H]-L-精氨酸转化为[3H]-L-瓜氨酸来测定培养的人脐静脉内皮细胞(HUVEC)中的NOS活性,并通过将[α-32P]-ATP转化为[32P]-环磷酸腺苷来测定腺苷酸环化酶活性。5. 异丙肾上腺素使脐静脉环舒张,这种血管舒张被β2-(而非β1-)肾上腺素能阻断、内皮去除或1 mM L-NMMA消除。此外,1 mM L-NMMA抑制了对二丁酰环磷酸腺苷的血管舒张反应,Emax从90.0±9.3%降至50.5±9.9%(P<0.05)。6. 1 μM异丙肾上腺素增加了HUVEC中的NOS活性(比基础值高34.0±5.9%,P<0.001)。此外,异丙肾上腺素以浓度依赖的方式增加腺苷酸环化酶活性;这种反应被β2-(而非β1-)肾上腺素能阻断所抑制。1 μM福斯可林和1 mM二丁酰环磷酸腺苷各自增加了HUVEC中的NOS活性,其程度与1 μM异丙肾上腺素相似。与NOS抑制剂共同孵育可消除每种药物观察到的L-精氨酸向L-瓜氨酸转化的增加。7. 这些结果表明,内皮β2-肾上腺素能刺激和环磷酸腺苷升高激活了L-精氨酸/NO系统,并导致人脐静脉血管舒张。